Introduction {#Sec1}
============

Disc herniation is a classic cause of spinal and radicular pain. Isolated lower back pain is a common symptom and has been estimated to affect up to 80 % of individuals at any time of their lives \[[@CR2]\]. In 98 % of cases, lower back pain is thought to be caused by degenerative changes in the lumbar spine, whereas the remaining 2 % of cases are attributed to other disorders. However, there is no clear relationship between clinical symptoms and radiological findings \[[@CR14], [@CR22], [@CR28]\]. Lumbar discectomy is commonly offered for treatment of sciatica due to disc herniation. However, literature reports on resolving back pain are non-conclusive, i.e., some results show significant improvement in reducing back pain \[[@CR3], [@CR11], [@CR25], [@CR29]\], whereas other papers present contradictory observations \[[@CR4], [@CR30]\].

One of the potential factors affecting pain perception is genetic diversity \[[@CR19]\]. Polymorphisms in the coding regions of the *COMT* gene result in altered enzymatic activity, and entails different pain-associated catecholamine and encephalin levels \[[@CR20]\]. Studies show that reduced COMT activity results in increased pain sensitivity in animal models and in humans \[[@CR8], [@CR20]\]. Clinical studies demonstrate also less prominent facial pain in patients characterized by lower COMT activity \[[@CR16]\]. Similarly, some studies reported that polymorphisms of the *COMT* gene resulting in reduced enzyme activity were associated with fibromyalgia \[[@CR10]\], temporomandibular disorder \[[@CR8], [@CR20]\], and affected morphine efficacy. Dai et al. \[[@CR7]\] postulated in their study of patients subjected to degenerative disc disease that genetic variation in the *COMT* gene might be one of the factors associated with pain sensitivity. The authors were able to reveal a borderline association (not statistically significant) between certain *COMT* haplotypes and pain intensity measured by VAS score after surgery.

Since there is no clear statement on the role of *COMT* polymorphism in pain perception in subjects after lumbar spine surgery, the present study was designed. It is aimed at the search for an association between *COMT* SNPs (single-nucleotide polymorphism) and haplotypes and pain sensitivity in patients with a history of leg and back pain, diagnosed with lumbar disc herniation (LDH), who subsequently underwent lumbar discectomy.

Materials and methods {#Sec2}
=====================

A total of 176 patients of Caucasian origin diagnosed with lumbar disc herniation and subjected to lumbar discectomy were recruited for the prospective study carried out at the Neurosurgery Department of Medical University of Gdansk, Poland, in 2009--2010. The main inclusion criterion was persistent back and leg pain resistant to conservative therapy for at least 6 months with lumbar disc herniation on CT or MRI scans. Surgery was performed on one of the levels from L3 to S1 by one of four neurosurgeons. The same midline standard posterior approach was used with the assistance of an intra-operative microscope. Exclusion criteria included: patients receiving narcotic pain medications, patients who had progression of symptoms and required immediate surgery, re-operation, fixed motor deficit, spinal stenosis, cauda equina syndrome, and spine deformities. Patients diagnosed with conditions which could influence their perception of pain, like mental disorder (depression) or polyneuropathy, were not eligible for this study. Any other comorbidities were not analyzed.

Patient clinical status was recorded by means of self-reported questionnaires: (Oswestry Disability Index (ODI) and visual analogue pain scale (VAS) separately for lower back pain---VAS~BACK~, and leg pain---VAS~LEG~), all completed before surgery and 12 months post-operatively with the aim to concentrate on chronic pain. For the purpose of this study, the first question from ODI was extracted. The study protocol was approved by the local ethics committee, and each patient signed informed consent forms.

Genotyping {#Sec3}
----------

SNPs within the *COMT* gene were evaluated using Taqman genotyping assays. Genomic DNA was extracted from 200 μl of whole blood samples using GeneMATRIX Quick Blood DNA Purification Kit (EURx, Poland). Pre-validated allelic discrimination TaqMan real-time PCR assays were used for detection of rs6269:G \> A, rs4633:C \> T, rs4818:C \> G, and rs4680:G \> A SNPs (respective assay IDs: C\_\_\_2538746_1, C\_\_\_2538747_20, C\_\_\_2538750_10, and C\_\_25746809_50) (Applied Biosystems, California, USA). Fluorescence data was captured using 7500 FAST Real-Time PCR System (Applied Biosystems), after 40 cycles of PCR. Haplotypes were classified in according to *COMT* activity, A_C\_C_G -- low, A_T\_C_A -- medium and G_C\_G_G -- high activity. Diplotype was assigned to each patient and data were further analyzed.

Statistical analysis {#Sec4}
--------------------

Associations between categorical variables were assessed by Chi-square test. Analysis of associations between *COMT* genotypes and clinical parameters was performed by means of Mann--Whitney *U* test. General linear model was used for multivariate analysis. A *p* value of less than 0.05 was considered statistically significant. Calculations were performed using the Statistica 7.1 software package (StatSoft, Oklahoma, USA). The EH program (Rockefeller University) was used to estimate haplotype frequencies.

Results {#Sec5}
=======

The data from 176 patients, 73 females (41.5 %) and 103 males (58.5 %), aged 20 to 80 years (mean age, 46.7 ± 13.2 years) was collected. Distribution of *COMT* SNPs rs6269:A \> G, rs4633:C \> T, rs4818:C \> G and rs4680:A \> G were in agreement with Hardy-Weinberg equilibrium (*p* \> 0.7). The frequencies of *COMT* "low" A_C\_C_G, "medium" A_T\_C_A and "high" G_C\_G_G activity haplotypes were calculated (Fig. [1](#Fig1){ref-type="fig"}). The most common *COMT* haplotypes were these of "medium" (49.1 %) and "high" (39.5 %) activity, the "low" activity haplotype A_C\_C_G was found in 11.1 % of patients. No associations between *COMT* genotypes or haplotypes with gender were found.Fig. 1Illustration of incidence of different SNPs, depicted on the right are minor allele frequencies

Homozygous *COMT* rs6269 *AA* patients demonstrated a trend towards lower pain intensity preoperatively (pain intensity in Oswestry score) (*p* = 0.056) as well as lower pain intensity at 1 year after the surgery *p* = 0.091 in comparison with G allele carries. Significantly lower postoperative pain intensity was experienced by rs6269 *G* subjects (*p* = 0.02 *GG* + *GA* vs. *AA*). Patients who were homozygous for *COMT* rs6269 *A* demonstrated also a significantly lower preoperative back pain VAS~BACK~ (*p* = 0.045) compared with the GG genotype subjects. Non-significant trend was observed for VAS~BACK~ improvement in *GG* subjects in comparison with other genotypes (*p* = 0.053) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Distress amplitude and magnitude of recovery by genotype groupGenotype rs6269Genotype rs4633Genotype rs4818Genotype rs4680TraitsGGGAAATTTCCCGGGCCCAAAGGGPreoperative ODI29.0 ± 8.626.14 ± 9.425.4 ± 9.423.65 ± 9.726.47 ± 9.328.14 ± 8.929.03 ± 8.626.13 ± 9.425.07 ± 9.523.60 ± 9.826.40 ± 9.228.13 ± 8.8Postoperative ODI18.96 ± 10.4017.62 ± 11.515.2 ± 9.215.20 ± 8.617.54 ± 11.717.5 ± 10.118.96 ± 10.417.54 ± 11.515.26 ± 9.315.30 ± 8.717.47 ± 11.717.5 ± 10.1ODI change−10.10 ± 12.19−8.51 ± 12.6−9.9 ± 9.6−8.45 ± 8.6−8.93 ± 12.9−10.63 ± 11.1−10.07 ± 12.1−8.59 ± 12.5−9.80 ± 9.7−8.31 ± 8.6−9.0 ± 12.9−10.63 ± 11.1Preoperative pain intensity3.55 ± 0.753.6 ± 1.132.9 ± 1.42.68 ± 1.53.16 ± 1.13.41 ± 0.93.55 ± 0.83.15 ± 1.12.85 ± 1.42.67 ± 1.53.16 ± 1.13.41 ± 0.9Postoperative pain intensity2.25 ± 1.651.92 ± 1.71.4 ± 1.41.22 ± 1.31.96 ± 1.72.0 ± 1.52.25 ± 1.61.90 ± 1.71.41 ± 1.41.25 ± 1.31.93 ± 1.72.0 ± 1.5Pain change−1.29 ± 1.8−1.22 ± 1.8−1.5 ± 1.7−1.49 ± 1.7−1.20 ± 1.8−1.41 ± 1.7−1.29 ± 1.8−1.24 ± 1.8−1.44 ± 1.7−1.49 ± 1.7−1.22 ± 1.8−1.41 ± 1.7Preoperative VASBACK7.74 ± 1.916.65 ± 2.76.39 ± 2.96.13 ± 3.06.65 ± 2.77.39 ± 2.16.33 ± 2.96.69 ± 2.77.74 ± 1.96.04 ± 3.06.71 ± 2.77.39 ± 2.1Postoperative VASBACK4.44 ± 2.484.71 ± 3.04.07 ± 2.84.29 ± 2.54.72 ± 3.174.06 ± 2.64.11 ± 2.84.68 ± 3.04.44 ± 2.54.34 ± 2.54.68 ± 3.24.06 ± 2.5VASBACK change−3.29 ± 2.65−1.94 ± 2.6−2.31 ± 3.3−1.84 ± 3.0−1.95 ± 2.9−3.32 ± 2.6−2.22 ± 3.3−2.01 ± 2.6−3.29 ± 2.7−1.69 ± 2.9−2.02 ± 3.0−3.32 ± 2.6Preoperative VASLEG7.66 ± 1.837.03 ± 2.46.75 ± 3.06.48 ± 3.37.16 ± 2.47.28 ± 2.16.69 ± 3.07.06 ± 2.47.66 ± 1.86.40 ± 3.37.20 ± 2.47.28 ± 2.1Postoperative VASLEG3.74 ± 2.84.44 ± 3.43.46 ± 2.93.40 ± 2.74.22 ± 3.54.08 ± 2.93.52 ± 2.94.39 ± 3.43.74 ± 2.83.48 ± 2.74.17 ± 3.54.08 ± 2.9VASLEG change−3.92 ± 3.31−2.58 ± 3.7−3.28 ± 3.5−3.07 ± 3.3−2.94 ± 3.9−3.19 ± 3.4−3.17 ± 3.5−2.67 ± 3.7−3.92 ± 3.4−2.91 ± 3.2−3.02 ± 3.9−3.19 ± 3.4*ODI* Oswestry Disability Index, *VASLEG,VASBACK* visual analog scale for sciatica and low back painTable 2Statistical significances of differences in clinical factors between clinical factors in separate genetic groups. Numbers in *bold* indicate *p* \< 0.05Preoperative ODIPostoperative ODIODI changePreoperative pain intensityPostoperative pain intensityPain changePreoperative VAS BACKPostoperative VAS BACVAS BACK changePreoperative VAS LEGPostoperative VAS LEGVAS LEG changers6269 GG vs. AA + GA0.140.230.990.0560.0910.82**0.045**0.910.0530.270.750.16 AA vs. GG + GA0.290.140.540.093**0.020**0.380.280.210.870.680.150.51rs4633 TT vs. TC + CC0.0680.340.63**0.0440.010**0.470.150.780.270.480.260.97 CC vs. TC + TT0.140.580.560.0510.240.780.0820.36**0.0042**0.760.670.799rs4818 GG vs. GC + CC0.1470.230.990.0550.090.820.180.260.910.520.220.68 CC vs. GC + GG0.310.160.610.10**0.031**0.47**0.045**0.910.0530.270.750.16rs4680 AA vs. AG + GG0.0710.390.55**0.0480.018**0.590.0920.910.160.340.380.79 GG vs. AG + AA0.140.580.560.0510.240.780.0830.36**0.0042**0.760.670.79

Statistical analysis of *COMT* rs4633 polymorphism point out significantly lower pain intensity in both pre- (*p* = 0.044) and postoperative (*p* = 0.010) period in *TT* genotype carriers vs. *TC* + *CC* genotypes. In homozygous *CC* patients, higher scores in VAS~BACK~ scale before surgery were recorded. Significantly higher VAS~BACK~ improvement in CC carriers in comparison with other genotypes (*p* = 0.0042) was noted. No association between SNP *COMT* rs4818 and improvement in ODI or VAS changes was found. However, patients with *CC* genotype demonstrated significantly lower pain intensity in postoperative ODI (*p* = 0.031). Additionally, carriers of *CC* genotype showed significantly higher preoperative VAS~BACK~ score compared with *GC* + *GG* patients. *CC* subjects tended to have better clinical outcome one year after surgery (*p* = 0.055) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Association of COMT rs4680 polymorphism with ODI and VAS scores is presented in Table [1](#Tab1){ref-type="table"} with *p* values shown in Table [2](#Tab2){ref-type="table"}. Carriers of *AA* genotype presented lower pain intensity in ODI pre- (*p* = 0.048) and postoperatively (*p* = 0.018), though improvement rate was not significant (*p* = 0.59). In patients with *GG* genotype, a trend towards higher preoperative pain intensity in ODI and significantly better clinical outcome recorded in VAS~BACK~ score in comparison with other genotypes were observed (*p* = 0.0042) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2**a**--**d** Plots of changes in different pain scales after surgery and 1-year follow-up, grouped by distinct genotypes. *Asterisk* (\*) depicts differences with *p* \< 0,05. (*A*)---denotes minor allele, (*B*)---major allele

The carrier status of at least one copy of *COMT* A_C\_C_G haplotype determines low metabolic activity of COMT enzyme, and patients with at least one copy of A_C\_C_G haplotype show better clinical outcome measured by ODI score, compared with non-carriers, who inherited a combination of G_C\_G_G, A_T\_C_A or A_T\_G_G haplotypes (i.e., subjects without A_C\_C_G haplotype), although the recorded improvement in ODI score was only borderline significant (*p* = 0.079, Table [3](#Tab3){ref-type="table"}). However, the effect of A_C\_C_G haplotype was reflected by the improvement in VAS~BACK~ score as compared with non-carriers (*p* = 0.017). Because of the presence of *COMT* G_C\_G_G (high activity) haplotype is equivalent to the presence of rs6269 *G* allele and the presence of A_T\_C_A (medium) haplotype is equivalent to the presence of rs4680 *A* allele, associations of these haplotypes with the evaluated parameters are equal to the respective genotypes. However, haplotype "low" is not equivalent to the presence of any of the studied genotypes (the respective results are presented in Table [3](#Tab3){ref-type="table"}).Table 3Patients' clinical evaluation in patients classified based on the presence of COMT A_C\_C_G haplotype, determining low enzyme activityHaplotype L (A_C\_C_G)Present vs. absentAbsent (*n* = 138)Present (*n* = 38)*p* valuePreoperative ODI25.79 ± 9.4927.68 ± 8.820.27Postoperative ODI17.36 ± 10.6915.42 ± 10.200.28ODI change−8.42 ± 11.6−12.26 ± 10.440.079Preoperative VAS BACK6.68 ± 2.736.89 ± 2.420.81Postoperative VAS BACK4.65 ± 2.83.65 ± 2.970.052VAS BACK change−2.08 ± 2.78−3.23 ± 3.12**0.017**Preoperative VAS LEG7.01 ± 2.657.06 ± 2.230.77Postoperative VAS LEG3.97 ± 3.174.07 ± 3.20.92VAS LEG change−3.04 ± 3.56−3.03 ± 3.730.98Significance for bold numbers in all the text (including tables) is *p* \< 0.05

Multivariate general linear models adjusted for patients' age and gender and *COMT* genotypes (Table [4](#Tab4){ref-type="table"}) showed that the presence of at least one copy of rs4633 *T* or rs4626 *A* allele or *COMT* L A_C\_C_G haplotype (due to a strong linkage disequilibrium, these variables could not be analyzed in one model) are independent predictors of better clinical response (by 1.2 and 1.45 in VAS~BACK~, *p* = 0.0032 and *p* = 0.046, respectively). Haplotype "low" activity was also markedly, but statistically insignificantly, associated with clinical improvement in ODI (by 4.1, *p* = 0.051).Table 4General linear regression models of factors potentially associated with back pain intensityIndependent variablesVASBACK change*p* valueRegression coefficientAge0.0140.38Male sex0.590.17Presence of rs4633 allele T**−1.450.0032**Independent variablesVASBACK change*p* valueRegression coefficientAge0.0120.44Male sex0.530.22Presence of rs4680 allele A**−1.20.046**Independent variablesVASBACK change*p* valueRegression coefficientAge0.010.47Male sex0.660.13Presence of COMT haplotype L**−1.30.014**Independent variablesODI change*p* valueRegression coefficientAge0.0090.89Male sex2.360.18Presence of COMT haplotype L**−4.140.051**Significance for bold numbers in all the text (including tables) is *p* \< 0.05

Discussion {#Sec6}
==========

In spite of recent advances in surgical technique, effective pain treatment in patients suffering from lumbar spine pathology still remains a considerable clinical problem. Surgical intervention criteria in those patients are clear-cut in case of cauda equina syndrome or progressive motor deficit, but elective surgery is based on individual decision \[[@CR6], [@CR13], [@CR23], [@CR26], [@CR27]\]. The latter approach is partly caused by the use of various pain-assessment tools, and even those considered as a "gold standard" in evaluation of surgery results still lack validation \[[@CR6]\]. Problems with decision-making in patient classification for surgery or conservative treatment may also result from interindividual differences in pain threshold that may be determined at least partly by genotype.

The first direct evidence that *COMT* polymorphism affects neural processing of pain was reported by Zubieta et al. \[[@CR31]\], who noted that COMT 158met (rs4680) homozygotes were characterized by higher pain sensitivity, diminished regional μ-opioid system responses to pain, as well as a higher μ-opioid receptor binding potential, in comparison with heterozygotes and 158 val homozygotes. Additionally, Loggia et al. \[[@CR15]\] provided information on *COMT* val158met polymorphism involvement in pain perception in response to heat stimuli. The authors found that met/met subjects exhibited stronger pain-related fMRI signals than val/val in several brain structures. Therefore, met/met patients might be characterized by lower pain threshold and higher risk of chronic pain development. Our own observations in patients suffering from chronic lumbar pain did not support the aforementioned reports, since no significant associations between *COMT* val158met polymorphism and VAS/ODI score have been found, except for better response to treatment in GG (val/val) cases.

However, analyzing solely pre- and postoperative pain intensity it can be seen, that *AA* subjects were characterized by markedly lower pain intensity measures vs. *G* allele carriers. Contribution of other *COMT* genotypes to pain perception does also support a modulatory effect of these genetic parameters. Significantly lower preoperative pain intensity was experienced by 4633 *TT*, 4680 *AA* and higher in 4818 *GG* subjects, whereas postoperative pain intensity was markedly decreased in 4633 *TT*, 4818 *CC*, 4680 *AA* and 6269 *AA* carriers. Also, local pain perception in LDH patients was associated with *COMT* polymorphism, and preoperative VAS~BACK~ was the most prominent in patients characterized by 6269 *GG* and 4818 *CC* genotypes. Likewise, *COMT* polymorphism significantly modulated response to surgery (VAS~BACK~ change), i.e., the best outcomes were observed in 6269 *CC*, 4633 *CC*, and 4680 *GG* carriers. These observations are supported by linear regression analysis, which demonstrated that *COMT* rs4633 *T* allele and rs4680 *A* allele are independent risk factors for VAS~BACK~ change (Table [4](#Tab4){ref-type="table"}). The observed differences in pain perception in patients of various genetic constitutions may enable identification of subjects particularly predisposed to chronic pain development, and thus requiring more intensive analgesic treatment. Our findings are in agreement with the report by Jacobsen et al. \[[@CR12]\], who revealed that *COMT* val158met polymorphism could contribute to discogenic subacute low back pain and sciatica in degenerative disc disease, since val/val patients (like in the present study) were characterized by the largest reduction in postoperative pain in comparison with met/val and met/met carriers. Associations between *COMT* gene SNPs and pain were also evaluated by Dai et al. \[[@CR7]\], using ODI and VAS, in a group of patients subjected to surgical treatment for LDH. The authors reported that patients homozygous for *COMT* rs4633 *T* allele were characterized by most prominent mean improvement in ODI score one year after surgery, which was not observed in our study (response measured by ODI change was similar in all rs4633 genotypes). Contrary to the present results Dai et al. \[[@CR7]\] did not reveal significant impact of other studied SNPs, i.e., rs6269, rs4818 and rs4680 on pain perception.

Recent studies suggest that *COMT* haplotypes, rather than individual SNPs, would be more appropriate for the prediction of COMT biological effects \[[@CR8], [@CR31]\]. Even silent mutations that usually do not change the amino-acid sequence may affect function through alterations in COMT mRNA structure and stability, thus influencing disease risk or treatment efficacy. Diatchenko et al. \[[@CR8]\] revealed a strong association between a specific *COMT* haplotype - G_C\_G_G and pain sensitivity, and an inverse correlation between pain sensitivity and COMT activity in healthy subjects. Low sensitivity to experimental pain was associated with G_C\_G_G haplotype (high activity haplotype), whereas A_C\_C_G haplotype (low activity) was associated with high pain sensitivity. Dai et al. \[[@CR7]\] also reported that *COMT* haplotype status was associated with pain perception in patients undergoing surgical treatment for lumbar degenerative disc disease. Patients with A_T\_C_A haplotype responded most effectively to the surgical procedure, and were followed by subjects carrying G_C\_G_G haplotype and A_C\_C_G, haplotype, as measured by ODI score. Our findings are contrary to observations of Dai et al., who found that A_C\_C_G haplotype patient were characterized by significantly higher postoperative VAS~BACK~ pain, and responded less effectively to treatment (VAS~BACK~ change). Likewise, linear regression analysis applied in the present study indicated that *COMT* A_C\_C_G haplotype was an independent risk factor for VAS~BACK~ and possibly ODI changes (Table [3](#Tab3){ref-type="table"}). Recently, a study of McLean et al. \[[@CR17]\] has confirmed the opinion that individuals with *COMT* pain vulnerable genotype A_C\_C_G were at increased risk of acute pain and needed preventive interventions. The authors evaluated an association between *COMT* genotype and acute neck pain intensity in individuals after motor vehicle collision, and found that individuals characterized by *COMT* A_C\_C_G haplotype were more likely to report moderate-to-severe neck pain, headache, and dizziness. Moreover, patients with genotype coding low COMT enzyme activity were found to have longer time to physical and emotional recovery. Likewise, Tchivileva et al. \[[@CR24]\], studying an association between common *COMT* haplotypes and response to β-blocker treatment in a common chronic musculoskeletal pain disorder, found that carriers of low and medium *COMT* activity haplotype showed the most prominent response to propranolol in all pain measures except for thermal threshold. Patients carrying *COMT* A_C\_C_G haplotype demonstrated not only more efficient response to pharmacological treatment but also better surgical treatment outcome.

Pain analysis is problematic due to its subjective nature and broad range of factors modulating it, such as ethnicity as evidenced by known differences in both pain perception and reporting between African Americans and Caucasians \[[@CR5], [@CR9]\]. This may be related to *COMT* rs4680 158met frequency in various populations, ranging from 0.01 to 0.62 \[[@CR21]\]. This fact creates difficulties in developing reliable scales characterizing pain. As Polish population in 98 % consists in Caucasian and additionally ethnic differences in catechol-*O*-methyltransferase activity is confirmed \[[@CR1], [@CR18]\] we found it reasonable to focus only on one ethnic group. Undoubtedly, to confirm our results, further studies in Asian or African American populations should be designed.

In conclusion, the aim of this study was to find a potential correlation between genetic polymorphism of the *COMT* enzyme and pain perception. This association was observed in patients with the COMT SNP rs4633 *CC*, rs4680 GG, who demonstrated greater reduction of low back pain in 1 year after surgery. This fact may have potential clinical implication in decision-making, e.g., selection of those subjects for earlier surgery. We believe that the lack of correlation between COMT activity and reduction of leg pain (VAS~LEG~) after surgery can be explained by the pivotal role of direct nerve root decompression during surgery. As for the present study, the studied group of patients is too small to draw arbitrary conclusions regarding genetic diversity in COMT and its role in predicting clinical outcome after lumbar discectomy. The observed associations suggest that it is not possible to make a clinical decision on operation or conservative treatment based solely on the COMT gene polymorphism. However, the COMT genotype may serve as a tool indicating patients who will benefit more from surgery, being one of the factors behind decision-making, along with other parameters (like radiological findings, clinical status); to some extent, pharmacogenetics may play a supportive role as a prognostic factor. However, given a relatively small group size, larger studies are needed in order to confirm the value of the present study observations.
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